Carolyn Sutton’s Post

Published today is a webinar discussion between Dr G. Michael Lewitt and Dr Omar Noor on the impact of bimekizumab for plaque psoriasis in clinical practice. While they discuss the MOA, efficacy and safety profile, I imagine the listeners will equally value the patient anecdotes highlighted. Watch ~16 minutes or read the summary. Link in comment below.

Our depth of expertise ensures precision and innovation in every dermatological study we undertake. We manage global Phase II-III trials in conjunction with our standalone Phase I unit. Trust TKL Research for a journey of excellence in dermatology research. #TKLResearch #DermatologyExpertise #ClinicalInnovation

Now available: New congress report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (#EADV)! In this report, 2022 IPC Fellow Juul van den Reek has compiled thirteen summaries of the latest and most inspiring presentations on psoriasis at this year’s EADV, including IPC’s symposium and late-breaking sessions. Read the summary or download the full report: https://lnkd.in/g_wx63ZU #IPCCongressReport #PsoriasisNews

I am privileged to share our new article published in the American Journal of Clinical Dermatology, which focuses on the use of topical calcineurin inhibitors on atopic dermatitis patients among the Taiwanese population. Please feel free to discuss and share your comments with me! https://lnkd.in/gYnFpfMh #atopicdermatitis #cohortstudy #topicalcalcineurininhibitors #NationalHealthinsuranceResearchDatabase

Check out the latest Dermatology MEDCast!

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment : In this Dermatology Times article, listen to Christopher Bunick, MD, PhD, as he delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis. https://lnkd.in/gsDAMw86

New Publication in Dermatology and Therapy: The analysis of an IL-13 inhibitor across EASI body regions and clinical signs of Atopic Dermatitis, results from ADvocate 1 & ADvocate 2 trials. View the full publication here: https://e.lilly/4ayAaKR

Lawrence Eichenfield, M.D., discusses studies from the 2024 American Academy of Dermatology Annual Meeting that have significant implications for the management of atopic dermatitis (AD). Watch this K-Cast episode to learn more about key insights on AD from #AAD2024 https://bit.ly/3V8OQvC #AtopicDermatitis #ManagedCare https://bit.ly/3V8OQvC

Good news! Dermatomyositis treatment options could grow exponentially in the next few years, according to David Fiorentino, MD, PhD, professor of dermatology at Stanford University. Watch now to learn more: https://lnkd.in/eVHZkYQX #Myositis #MyositisWarrior #MyositisAwareness #TheMyositisAssociation #MyositisSupport #RareDisease #MYOMovement #MyositisLife #MyTMA #PatientAdvocacy #TheMyositisAgenda #MyTMA #MyoNews #TMAIAPC24 #myositisIAPC2024 #TheMyositisAgenda

🎇 Meet one of #EADVCongress plenary lecture speakers! Jonathan Barker is Professor of Medical Dermatology at St John’s Institute of Dermatology based at King’s College and Guy’s and St Thomas’s Hospitals, London. For much of his career his focus has been on the science and practice of psoriasis. In his lecture at the upcoming #EADVCongress in Amsterdam, Prof Barker will pursue: ✔️ The clinical and pathophysiological differences between plaque and pustular forms of psoriasis ✔️ How these differences translate into treatments options for pustular forms of psoriasis ✔️ New clinically useful ways of classifying psoriasis ⌛ You can already start planning your Congress journey! >> eadv.org/congress